Use of the monoclonal antibody anti-human epidermal growth factor receptor 2 (anti-HER2), trastuzumab, in the treatment of metastatic breast cancer: a cost-effectiveness analysis.
Poncet
B
B
Bachelot
T
T
Colin
C
C
Orfeuvre
H
H
Ganne
C
C
Péaud
P Y
PY
Jacquin
J P
JP
Salles
B
B
Tigaud
J D
JD
Méchin-Crétinon
I
I
Maréchal
F
F
Trillet-Lenoir
V
V
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy / Q000191:economics* / Q000556:secondary; D003362:Cost-Benefit Analysis; D005260:Female; D006801:Humans; D008875:Middle Aged; D011446:Prospective Studies; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism; D000068878:Trastuzumab; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab